FDA lifts hold on experimental Ebola drug from Tekmira

Culled from CBSNews

The U.S. Food and Drug Administration has eased safety restrictions on an experimental drug to treat Ebola, a move that could clear the way for its use in patients infected with the deadly virus.

Canadian drugmaker Tekmira Pharmaceuticals Corp. said the FDA modified a hold recently placed on the company's drug after safety issues emerged in human testing.

The company has a $140 million contract with the U.S. government to develop its drug, TKM-Ebola, which targets the genetic material of Ebola. But last month the FDA halted a small study of the injection in adults to request additional safety information. 

Tekmira said Thursday the agency "verbally confirmed" changes to the hold that may allow the company to make the drug available, although it has yet to be proven as safe and effective.

Given the emergency situation, the FDA may allow "compassionate consideration" for victims of Ebola, Rossi A. Hassad, an associate professor at Mercy College and a member of the American College of Epidemiology, told CBS News earlier this week. The FDA may also "expedite the processing of their applications on the clinical trials, and ease some of the bureaucracy."

Two Americans diagnosed with Ebola recently received a different experimental drug called ZMapp, made by Mapp Biopharmaceutical Inc. of San Diego. It is aimed at boosting the immune system's efforts to fight off Ebola and is made from antibodies produced by lab animals exposed to parts of the virus.

The U.S. aid workers were first treated in Liberia. And while the FDA must grant permission to use experimental treatments in the United States, it does not have authority over the use of such a drugs in other countries.

Currently, there are no licensed drugs or vaccines for the deadly disease. Several are in various stages of development, but none have been rigorously tested in humans.

The FDA in March granted Tekmira "fast track" status for its Ebola drug, a designation designed to speed up approval of high-priority drugs by granting companies extra meetings with FDA scientists. Early studies of TKM-Ebola in monkeys suggested it could block high doses of the Ebola virus. But on July 21, the company based in Vancouver, British Columbia, announced the FDA had halted a small dosing study of the drug in 28 healthy adults. The company said regulators had questions about a type of drug reaction that can cause nausea, chills, low blood pressure and shortness of breath.

Tekmira's CEO Mark Murray praised the FDA for modifying the restriction on Thursday.

"We have been closely watching the Ebola virus outbreak and its consequences, and we are willing to assist with any responsible use of TKM-Ebola," Murray said. "The foresight shown by the FDA removes one potential roadblock to doing so."